Development and validation of a nomogram to predict cardiac death after radiotherapy for esophageal cancer [0.03%]
食管癌放疗后预测心脏死亡的列线图的制定和验证
Xinfang Lv,Xue Wu,Kai Liu et al.
Xinfang Lv et al.
Background: Patients frequently die from cardiac causes after radiotherapy for esophageal cancer. Early detection of cardiac death risk in these patients is crucial to improve clinical decision-making and prognosis. Thus,...
Advances in medical treatment of advanced hepatobiliary and pancreatic cancer in 2022 [0.03%]
2022年晚期肝胆胰恶性肿瘤内科治疗进展
Le Zhang,Rui Liu,Ting Deng et al.
Le Zhang et al.
This article summarizes the drug therapy progress of advanced hepatocellular carcinoma, biliary tract cancer, and pancreatic cancer in 2022, including chemotherapy, molecular targeted therapy, and immunotherapy, to provide reference informa...
The landscape of investigator-initiated oncology trials conducted in mainland China during the past decade (2010-2019) [0.03%]
中国大陆近十年（2010-2019）肿瘤领域发起者发起的临床试验概况分析
Ye Cao,Lin-Miao Ye,Zhong Fan et al.
Ye Cao et al.
The number of clinical trials conducted in mainland China, including investigator-initiated trials (IITs), has increased rapidly in recent years. However, there are few data on the characteristics of cancer-related IITs. We performed a comp...
Annual progress of clinical research on targeted therapy for nonsmall cell lung cancer in 2022 [0.03%]
2022年非小细胞肺癌靶向治疗临床研究年度进展
Yan Huang,Li Zhang
Yan Huang
With the rapid development of lung cancer molecular detection and precision therapy, targeted therapy has covered the entire process of diagnosis and treatment of nonsmall cell lung cancer patients. Overall mortality from lung cancer has de...
Clustering of prostate cancer healthcare pathways in the French National Healthcare database [0.03%]
基于法国国家医疗保健数据库的前列腺癌诊疗路径聚类分析
Roméo Baulain,Jérémy Jové,Dunia Sakr et al.
Roméo Baulain et al.
Background: Healthcare pathways of patients with prostate cancer are heterogeneous and complex to apprehend using traditional descriptive statistics. Clustering and visualization methods can enhance their characterization...
Qi Wang,Chunxia Su,Caicun Zhou
Qi Wang
Lung cancer is the malignant tumor with the highest morbidity and mortality in China, and nonsmall cell lung cancer is a common form of lung cancer. After undergoing chemotherapy and molecular targeted therapy, the treatment of lung cancer ...
Jingtong Zhai,Yun Wu,Fei Ma et al.
Jingtong Zhai et al.
Breast cancer has replaced lung cancer as the most common malignancy worldwide. The 5-year survival rate of breast cancer has reached 90%. Systemic treatment of breast cancer has developed into a mature system including chemotherapy, target...
Adjuvant and neo-adjuvant immunotherapy in resectable non-small cell lung cancer (NSCLC): Current status and perspectives [0.03%]
可切除非小细胞肺癌（NSCLC）的辅助和新辅助免疫治疗：现状与展望
Ziyi Xu,Zihua Zou,Xuezhi Hao et al.
Ziyi Xu et al.
Surgery followed by adjuvant chemotherapy is the standard of care for selected patients with early-stage or locally advanced non-small cell lung cancer (NSCLC). However, many of these patients still experience postoperative recurrence at 5 ...
Ground glass nodules with scattered or eccentric island-shaped consolidations may have poor outcomes [0.03%]
散在或偏心岛状实变的磨玻璃结节预后可能较差
Ming Li,Junjie Xi,Huan Zhang et al.
Ming Li et al.
Background: To explore the effect of scattered or eccentric shaped types of ground glass opacity (GGO) on outcomes of patients with solid-dominant peripheral lung adenocarcinoma. ...
High BRCA1 expression is an independent prognostic biomarker in LUAD and correlates with immune infiltration [0.03%]
高BRCA1表达是肺腺癌的独立预后生物标志物且与免疫浸润相关
Fengzhu Guo,Cong Li,Shuning Liu et al.
Fengzhu Guo et al.
Lung adenocarcinoma (LUAD) patients with elevated breast cancer susceptibility gene 1 (BRCA1) expression had markedly worse overall survival and progression-free survival compared to those with reduced BRCA1 levels. In contrast, BRCA1 expre...